AUTHORS
Vera Adema, PhD, Prashanth Chakrapani, MS2, Cecile Karsenty, MD3, Francesco Pesce, MD4, Natthakan Thongon, PhD5, Xiaolin Li6, Ali Nasrollahzadeh, MSc7, Yiqian Gu8, Venee Tubman, MD MMSc9, Scott Alan Peslak I, MD,PhD10, Guillermo Garcia-Manero, MD11, David Kummer12, Simona Colla, PhD13
AFFILIATIONS
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 Texas Children's Hematology Center and Baylor College of Medicine, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, United States, UT MD Anderson Cancer Center, Houston, Texas, United States
8 University of California Los Angeles, Los Angeles, California, United States
9 Texas Children's Hematology Center and Baylor College of Medicine, Houston, Texas, United States
10 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
11 UT MD Anderson Cancer Center, Houston, Texas, United States
12 Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Heme-regulated inhibitor (HRI), a key kinase in the integrated stress response (ISR) that is activated in response to heme deficiency, is a promising therapeutic target in patients with sickle cell disease (SCD). In SCD patients, HRI inhibition suppresses BCL11A and induces γ-globin expression to increase fetal hemoglobin (HbF) production. In previous studies of patients with myelodysplastic syndromes with ringed sideroblasts and SF3B1 mutations, we showed that HRI activation blocks terminal erythroid differentiation, leading to the characteristic anemia seen in these patients. Mechanistically, SF3B1 mutations cause the aberrant splicing of mitochondrial heme transporters, leading to an abnormal accumulation of heme within the mitochondria and subsequent HRI activation. Deletion of the HRI gene (EIF2AK1) with CRISPR/Cas9 overcomes the block in the terminal erythroid differentiation caused by SF3B1 mutations, in part by increasing the expression of mitochondrial heme transporters. These findings suggest that the pharmacologic inhibition of HRI is a shared therapeutic strategy in erythroid disorders and support the development of HRI inhibitors (Adema et al., BCD 2022).
Increasing the HbF levels in red blood cells offers clinical benefits to patients with SCD, which is induced by β-globin germline mutations that lead to abnormal adult hemoglobin formation and erythrocyte sickling. In erythroblasts, EIF2AK1 activates BCL11A, a key suppressor of HbF production throughout life. Genetically targeting EIF2AK1 decreases BCL11A levels, increases HbF production, and decreases erythrocyte sickling. Therefore, we hypothesized that pharmacologically inhibiting EIF2AK1 activation can overcome the deleterious effects of SCD observed in SCD patients. Using virtual screening and structural insights from other ISR kinase family inhibitors, we developed several compounds with good selectivity for HRI (relative to other ISR family members), good cell target engagement, low nanomolar potency, and high permeability. Two compounds, IACS-18148 and IACS-18795, inhibited the catalytic activity of HRI at half-maximal inhibitory concentrations of 7.2 and 1.3 nM, respectively, and had 140- and 1,000-fold selectivity, respectively, for HRI over other ISR family members.
Following treatment with IACS-18148 (n=5) or IACS-18795 (n=6), erythroblasts derived from CD34+ cells isolated from SCD patients and cultured in erythroid differentiation conditions for 15 days showed increased fetal hemoglobin (HBG1/2) expression by 6.8-fold (P=0.0078) and 2.9-fold (P=0.0154), respectively, and reduced BCL11A expression by 20% and 10%, respectively, suggesting that other mechanisms can contribute to the HbF increase. To assess the target engagement of IACS-18795 in vivo, we injected CD34+ SCD cells into immune-deficient mice (NBSGW); 24 weeks later, we performed bone marrow aspiration analysis, and mice showing high human cell reconstitution were treated with vehicle (n=8) or IACS-18795 (100 mg/kg; n=8) for 21 consecutive days. Bone marrow mouse Ter119- cells and human CD45- and CD235A+ cells were sorted by flow cytometry for single-cell RNA sequencing, which showed three major erythroid clusters. Differential expression analysis showed the upregulation of major transcription factors involved in erythroid differentiation, including GATA1, KLF1, TFRC, and ALAS2 (Padj 0.05, <0.001, <0.001, <0.001; respectively), in IACS-18795 treated–cells compared with vehicle-treated controls. Globin gene expression analysis showed increased HBA1, HBA2, and HBG1 expression (Padj <0.001, <0.001, <0.001; respectively), but decreased HBB expression (Padj <0.001), in treated cells relative to controls. These clusters also had upregulated cytoplasmic translation, ribosome biogenesis, and OXPHOS signatures, which indicates an active metabolic state supporting erythropoiesis. Additionally, compared with vehicle-treated cells, IACS-18795–treated cells showed downregulation of the cell cycle program, which suggests progression towards terminal erythroid differentiation, and downregulation of autophagy pathway members, including GABARAPL1/2, MAP1LC3B, and SNCA (Padj <0.001/<0.001, <0.001, <0.001; respectively) which are known to mediate painful vaso-occlusive crises in SCD patients. These results suggest that HRI inhibitors effectively induce HbF production and therefore show promise as disease-modifying agents in SCD.
DISCLOSURES
Vera Adema, PhD: No relevant conflicts of interest to declare.